<SEC-DOCUMENT>0001193125-17-095574.txt : 20170324
<SEC-HEADER>0001193125-17-095574.hdr.sgml : 20170324
<ACCEPTANCE-DATETIME>20170324160703
ACCESSION NUMBER:		0001193125-17-095574
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170320
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170324
DATE AS OF CHANGE:		20170324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		17712844

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d351880d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) March&nbsp;20, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (267)&nbsp;440-4200 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><U>Item&nbsp;5.02</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</U>. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2017, George W. Bickerstaff III was appointed as a director of our company effective March&nbsp;21, 2017.
Mr.&nbsp;Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. Mr.&nbsp;Bickerstaff is currently a partner and the managing director of M.M. Dillon&nbsp;&amp; Co., a healthcare and technology
investment bank that he co-founded in 2005. In this role, he has advised dozens of companies on business strategy and financial and capital market issues. He has served Novartis Pharma AG as its chief financial officer from 2000 to 2005 and held
senior financial positions at IMS Health from 1989 to 1997 and previously held financial positions with Dun&nbsp;&amp; Bradstreet and General Electric. He currently serves as a member of the boards of directors of the following companies: ARIAD
Pharmaceuticals, Inc. (NasdaqGS: ARIA); Cardax, Inc. (OTCQB: CDXI); and CareDx, Inc. (NASDAQ: CDNA). He holds a B.S. in Engineering and B.A. in Business Administration from Rutgers University and continued his executive education at Harvard Business
School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2015, Mr.&nbsp;Bickerstaff was granted an option to purchase 20,000 shares of our common stock at an exercise
price of $5.86 per share and restricted stock units representing 12,270 shares of our common stock. Mr.&nbsp;Bickerstaff will also receive the same cash and equity compensation that is paid to our other outside directors for their service as
directors and as members of our board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated March&nbsp;21, 2017</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Kies,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;24, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d351880dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g351880snap0001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>NEWS RELEASE </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211,
<U>jrichardson@inovio.com</U> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>George Bickerstaff Elected to Inovio&#146;s Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Former Novartis CFO brings finance, fundraising and M&amp;A experience to Inovio </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; March&nbsp;21, 2017 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the election of George Bickerstaff to its
Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. He has served
Novartis Pharma AG as its chief financial officer and held senior financial positions at IMS Health, Dun&nbsp;&amp; Bradstreet and General Electric. He serves on numerous boards and is currently partner and managing director of M.M.
Dillon&nbsp;&amp; Co., an investment bank and financial advisory firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President and CEO, said, &#147;George
Bickerstaff&#146;s finance, operations and international business experience will be an asset to Inovio as we advance our products to commercialization and enter collaborative arrangements with other companies. The addition of George to our Board
helps ensure that Inovio will continue to benefit from a deep and wide range of experience.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported
generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a
growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital
resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of
funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain development and </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its
collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary
rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or
defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured,
that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g351880snap0001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g351880snap0001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MAGD,LK!5!B(Y- $^L>*=+T1O+N9B\^,^5&-S?CZ4 82_$NP+X:QN OKE3^E
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M1T(H ZK0_!-WKD7]H7]TT$<QW D;G?WYZ4 :5Y\-$$#-97[F4#A95&#^(Z4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
'H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
